Involvement of AMP-activated protein kinase in TGF-β-stimulated VEGF synthesis in osteoblasts

International Journal of Molecular Medicine

Volumn 29, Issue 4, 2012, Pages 550-556

  Mizutani, Jun ^a   Tokuda, Haruhiko ^b,c   Matsushima Nishiwaki, Rie ^b   Kato, Kenji ^a,b   Kondo, Akira ^a,b   Natsume, Hideo ^a,b   Kozawa, Osamu ^b   Otsuka, Takanobu ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Adenosine 5 monophosphate activated protein kinase; Mitogen activated protein kinase; Osteoblast; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN AMPK ALPHA; PROTEIN AMPK BETA; PROTEIN C JUN; SMAD2 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; CELL LINE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; OSTEOBLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858268921     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.893     Document Type: Article

References (49)

1. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
2. Karsenty G and Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2: 389-406, 2002. (Pubitemid 34436569)
3. Erlebacher A, Filvaroff EH, Gitelman SE and Derynck R: Toward a molecular understanding of skeletal development. Cell 80: 371-378, 1995.
4. Zelzer E and Olsen BR: Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 65: 169-187, 2005.
5. Saadeh PB, Mehrara BJ, Steinbrech DS, Dudziak ME, Greenwald JA, Luchs JS, Spector JA, Ueno H, Gittes GK and Longaker MT: Transforming growth factor-β1 modulates the expression of vascular endothelial growth factor by osteoblasts. Am J Physiol 277: C628-C637, 1999. (Pubitemid 29525901)
6. Tokuda H, Hatakeyama D, Akamatsu S, Tanabe K, Yoshida M, Shibata T and Kozawa O: Involvement of MAP kinases in TGF-β-stimulated vascular endothelial growth factor synthesis in osteoblasts. Arch Biochem Biophys 415: 117-125, 2003. (Pubitemid 36687924)
7. Kanno Y, Ishisaki A, Yoshida M, Tokuda H, Numata O and Kozawa O: SAPK/JNK plays a role in transforming growth factor-β-induced VEGF synthesis in osteoblasts. Horm Metab Res 37: 140-145, 2005. (Pubitemid 40547820)
8. Kuno M, Takai S, Matsushima-Nishiwaki R, Minamitani C, Mizutani J, Otsuka T, Harada A, Adachi S, Kozawa O and Tokuda H: Rho-kinase inhibitors decrease TGF-β-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Biochem Pharmacol 77: 196-203, 2009.
9. Fogarty S and Hardie DG: Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804: 581-591, 2010.
10. Yeh LA, Lee KH and Kim KH: Regulation of rat liver acetyl-CoA carboxylase. Regulation of phosphorylation and inactivation of acetyl-CoA carboxylase by the adenylate energy charge. J Biol Chem 255: 2308-2314, 1980. (Pubitemid 10036033)
11. Hardie DG, Hawley SA and Scott JW: AMP-activated protein kinase - development of the energy sensor concept. J Physiol 574: 7-15, 2006. (Pubitemid 43905792)
12. Lage R, Dieguez C, Vidal-Puig A, Lopez M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med 14: 539-549, 2008.
13. Steinberg GR and Kemp BE: AMPK in health and disease. Physiol Rev 89: 1025-1078, 2009.
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of AMP-activated protein kinase in mechanism of metformin activaiton. J Clin Invest 108: 1167-1174, 2001. (Pubitemid 32995375)
15. Kim EK, Miller I, Aja S, Landree JE and Pinn M: C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem 279: 19970-19976, 2004. (Pubitemid 38623439)
16. Nam M, Lee WH, Bae EJ and Kim SG: Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition. Arch Biochem Biophys 479: 74-81, 2008.
17. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, Korbonits M and Chenu C: AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 47: 309-319, 2010.
18. Sudo H, Kodama HA, Amagai Y, Yamamoto S and Kasai S: In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96: 191-198, 1983. (Pubitemid 13155577)
19. Kozawa O, Tokuda H, Miwa M, Kotoyori J and Oiso Y: Cross-talk regulation between cyclic AMP production and phosphoinositide hydrolysis induced by prostaglandin E2 in osteoblast-like cells. Exp Cell Res 198: 130-134,1992.
20. Natsume H, Tokuda H, Adachi S, Takai S, Matsushima-Nishiwaki R, Kato K, Minamitani C, Niida S, Mizutani J, Kozawa O, et al: Rho-kinase limits FGF-2-stimulated VEGF release in osteoblasts. Bone 46: 1068-1074, 2010.
21. Simpson DA, Feeney S, Boyle C and Stitt AW: Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR. Mol Vis 6: 178-183, 2000.
22. Kato K, Ito H, Hasegawa K, Inaguma Y, Kozawa O and Asano T: Modulation of the stress-induced synthesis of hsp27 and αB-crystallin by cyclic AMP in C6 rat glioma cells. J Neurochem 66: 946-950, 1996. (Pubitemid 26065890)
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
24. Kyriakis JM and Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807-889, 2001.
25. Moustakas A and Heldin CH: Non-Smad TGF-β signals. J Cell Sci 118: 3573-3584, 2005.
26. Hawley SA, Davison M, Woods A, Davies SP, Beri RK, Carling D and Hardie DG: Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem 271: 27879-27887, 1996. (Pubitemid 26367365)
27. Stein SC, Woods A, Jones NA, Davison MD and Carling D: The regulation of AMP-activated protein kinase by phosphorylation. Biochem J 345: 437-443, 2000. (Pubitemid 30099070)
28. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T and Neumann D: Dissecting the role of 5′-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 281: 32207-32216, 2006. (Pubitemid 46036775)
29. Mitchelhill KI, Michell BJ, House CM, Stapleton D, Dyck J, GambleJ, Ullrich C, Witters LA and Kemp BE: Posttranslational modifications of the 5′-AMP-activated protein kinase β1 subunit. J Biol Chem 272: 24475-24479, 1997. (Pubitemid 27418657)
30. Miyazawa K, Shinozaki M, Hara T, Furuya T and Miyazono K: Two major Smad pathways in TGF-β superfamily signalling. Genes Cells 7: 1191-1104, 2002.
31. Widmann C, Gibson S, Jarpe MB and Johnson GL: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 79: 143-180, 1999. (Pubitemid 29056951)
32. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E and Matsumoto K: Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270: 2008-2011, 1995.
33. Momcilovic M, Hong SP and Carlson M: Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 281: 25336-25343, 2006.
34. Emerling BM, Viollet B, Tormos KV and Chandel NS: Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett 581: 5727-5731, 2007. (Pubitemid 350179784)
35. Gao Y, Zhou Y, Xu A and Wu D: Effects of an AMP-activated protein kinase inhibitor, compoundC, on adipogenic differentiation of 3T3-L1 cells. Biol Pharm Bull 31: 1716-1722, 2008.
36. Wang DS, Yamazaki K, Nohtomi K, Shizume K, Ohsumi K, Shibuya M, Demura H and Sato K: Increase of vascular endothelial growth factor mRNA expression by 1,25-dihydroxyvitamin D3 in human osteoblast-like cells. J Bone Miner Res 11: 472-479, 1996.
37. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z and Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628, 1999. (Pubitemid 29289424)
38. Quinn JMW, Tam S, Sims NA, Saleh H, McGregor NE, Poulton IJ, Scott JW, Gillespie MT, Kemp BE and van Denderen BJW: Germline deletion of AMP-activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function. FASEB J 24: 275-285, 2010.
39. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, ShenJ, Vinson C, Rueger JM and Karsenty G: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207, 2000. (Pubitemid 30064908)
40. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM and Herzog H: Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109: 915-921, 2002. (Pubitemid 34275112)
41. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, et al: Leptin directly regulates bone cell function in vitro and reduces bone fragility invivo. J Endocrinol 175: 405-415, 2002. (Pubitemid 35414387)
42. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, KondoH, Richards WG, Bannon TW, Noda M, et al: Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434: 514-520, 2005. (Pubitemid 40477060)
43. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA and Ralston SH: Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11: 774-779, 2005. (Pubitemid 41021210)
44. Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C and Cocchi D: Ghrelin regulates proliferation and differentiation of osteoblastic cells. J Endocrinol 184: 249-256, 2005. (Pubitemid 40207579)
45. Ahn JD, Dubern B, Lubrano-Berthelier C, Clement K and Karsenty G: Cart overexpression is the only identifiable cause of high bone mass in melanocortin 4 receptor deficiency. Endocrinology 147: 3196-3202, 2006. (Pubitemid 43901110)
46. Sato S, Hanada R, Kimura A, Abe T, Matsumoto T, Iwasaki M, Inose H, Ida T, Mieda M, Takeuchi Y, et al: Central control of bone remodeling by neuromedin U. Nat Med 13: 1234-1240, 2007. (Pubitemid 47530632)
47. Hamrick MW and Ferrari SL: Leptin and the sympathetic connection of fat to bone. Osteoporos Int 19: 905-912, 2008. (Pubitemid 351758616)
48. Bonewald LF and Mundy GR: Role of transforming growth factor-βin bone remodeling. Clin Orthop Relat Res 261-276, 1990. (Pubitemid 20033993)
49. Kato K, Tokuda H, Adachi S, Matsushima-Nishiwaki R, Natsume H, Yamakawa K, Gu Y, Otsuka T and Kozawa O: AMP-activated protein kinase positively regulates FGF-2-stimulated VEGF synthesis in osteoblasts. Biochem Biophys Res Commun 400: 123-127, 2010.